CSTLHIGH SIGNALFINANCIAL10-K

Castle Biosciences experienced a dramatic financial deterioration with operating income swinging from $8.7M profit to -$42.8M loss despite significant revenue growth.

The company's shift from profitability to substantial losses indicates serious operational challenges despite growing its core business. The pivot away from mental health diagnostics to focus on atopic dermatitis suggests a strategic repositioning that may be impacting near-term profitability as the company invests heavily in new market development.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

Castle Biosciences showed mixed financial performance with gross profit surging 316% to $53.0M, indicating strong revenue growth and improved margins on core operations. However, this positive development was overshadowed by a 593% deterioration in operating income (from $8.7M profit to -$42.8M loss) driven by a 15% increase in SG&A expenses to $229.3M, suggesting heavy investment in sales and administrative functions. The company also increased capital expenditures by 27% to $36.0M and saw total liabilities rise 43% to $107.7M, indicating significant cash burn and growing financial obligations during this transition period.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-593.8%
$8.7M→-$42.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Gross Profit
P&L
+315.7%
$12.7M→$53.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Net Income
P&L
-232.4%
$18.2M→-$24.2M

Net income declined 232.4% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+42.8%
$75.4M→$107.7M

Liabilities grew 42.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+39%
$49.4M→$68.7M

Current liabilities surged 39% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
-35.3%
$17K→$11K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+27.2%
$28.3M→$36.0M

Capex increased 27.2% — ongoing investment in capacity or infrastructure for future growth.

Inventory
Balance Sheet
+26%
$8.1M→$10.3M

Inventory built 26% — monitor whether demand supports this build or if write-downs may follow.

Accounts Receivable
Balance Sheet
-15.3%
$51.2M→$43.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

SG&A Expense
P&L
+14.6%
$200.0M→$229.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 19, 2026, there were 29,731,198 shares of common stock, $0.001 par value per share, outstanding.
) and foreign countries; the performance of our third-party suppliers; the success of competing diagnostic products that are or become available; our ability to attract and retain key personnel; and our expectations regarding our ability to obtain and maintain intellectual property protection for our products and our ability to operate our business without infringing on the intellectual property rights of others.
Overview Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett s esophagus ( BE ), atopic dermatitis ( AD ), uveal melanoma ( UM ).
For our core tissue-based tests, we use multi-analyte assays with algorithmic analysis ( MAAA ) to characterize an individual patient s biology and generate clinically actionable information.
Depending on the specific test, this information may be used to provide information to help guide treatment and patient management decisions including potential responsiveness to therapy and to assist in the diagnosis of a disease.
+7 more — sign up free →
REMOVED
As of February 20, 2025, there were 28,514,109 shares of common stock, $0.001 par value per share, outstanding.
We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
Overview Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett s esophagus, uveal melanoma, and in the treatment of mental health conditions.
For our tissue based tests, we use multi-analyte assays with algorithmic analysis ( MAAA ) to characterize an individual patient s biology to inform specific risk of progression.
Test Portfolio and Market Overview Our portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology and ophthalmology and a pharmacogenomic ( PGx ) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →